Overview

Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients

Status:
Active, not recruiting

Trial end date:
2020-12-25

Target enrollment:

Participant gender:

Summary

This trial is a multi-center, open-label, randomized, parallel group trial in adult patients with T2DM comparing the efficacy and safety of GP40081 (insulin asapart mix 30, GEROPHARM) with that of NovoMix® 30 FlexPen®.

Phase:

Phase 3

Details

Lead Sponsor:

Geropharm

Treatments:

Biphasic Insulins
Insulin
Insulin Aspart
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin degludec, insulin aspart drug combination
Insulin, Globin Zinc
Insulin, Isophane
Insulin, Long-Acting